Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Bought by KCG Holdings Inc.
KCG Holdings Inc. boosted its stake in Fate Therapeutics, Inc. (NASDAQ:FATE) by 7.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 24,480 shares of the biopharmaceutical company’s stock after buying an additional 1,764 shares during the period. KCG Holdings Inc.’s holdings in Fate Therapeutics were worth $111,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in FATE. Creative Planning boosted its position in shares of Fate Therapeutics by 35.3% in the first quarter. Creative Planning now owns 23,000 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6,000 shares during the period. Hillsdale Investment Management Inc. bought a new stake in Fate Therapeutics during the first quarter worth $160,000. Segantii Capital Management Ltd bought a new stake in Fate Therapeutics during the first quarter worth $182,000. TFS Capital LLC bought a new stake in Fate Therapeutics during the first quarter worth $248,000. Finally, Bank of New York Mellon Corp raised its stake in Fate Therapeutics by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 59,510 shares of the biopharmaceutical company’s stock worth $271,000 after buying an additional 952 shares in the last quarter. 60.74% of the stock is currently owned by institutional investors.
Fate Therapeutics, Inc. (NASDAQ:FATE) traded up 2.49% during mid-day trading on Friday, reaching $2.88. The company’s stock had a trading volume of 31,190 shares. The firm’s market capitalization is $119.23 million. Fate Therapeutics, Inc. has a 52 week low of $1.80 and a 52 week high of $5.68. The company’s 50-day moving average price is $3.06 and its 200 day moving average price is $3.68.
Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by $0.03. Fate Therapeutics had a negative net margin of 857.34% and a negative return on equity of 75.93%. The business had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $1.04 million. On average, equities analysts forecast that Fate Therapeutics, Inc. will post ($1.00) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Bought by KCG Holdings Inc.” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/08/11/fate-therapeutics-inc-nasdaqfate-shares-bought-by-kcg-holdings-inc.html.
A number of research firms have weighed in on FATE. Wedbush restated an “outperform” rating and set a $7.00 target price on shares of Fate Therapeutics in a report on Tuesday, May 16th. ValuEngine lowered Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Monday. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Fate Therapeutics has an average rating of “Buy” and an average target price of $6.25.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Want to see what other hedge funds are holding FATE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fate Therapeutics, Inc. (NASDAQ:FATE).
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.